SynthesisClinical drug investigation2019

A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.

Daniel Gallacher et al.PubMed ↗Publisher ↗

No numbers read from the abstract.